Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9bn in strategic expansion
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN) have announced a definitive agreement where Vertex will acquire Alpine for $65 per share, amounting to approximately $4.9 billion in cash. This transaction, unanimously approved by both companies’ Boards of Directors, is set to close […]